Clinical Trial Update: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

This clinical trial update reports safety and efficacy data from a Phase 2 extension study of daclizumab high yield process (DAC HYP) in participants with relap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Daclizumab High Yield Process (DAC HYP) (daclizumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2016-08-30